Finimize - 📉 2023 has price-drop potential

Hi Reader, here's what you need to know for December 13th in 3:09 minutes.

💸 Want to make smarter investment decisions? Now you can develop your financial know-how with 6 months of free Finimize Premium, and unlock ultimate financial power with 3 months of free Revolut Premium too. We’ll even give you £10 (or equivalent) just for signing up.

Get it all for free today

Today's big stories

Biotech giant Amgen announced it’s buying Horizon Therapeutics
Here's why prices might finally drop next year – Read Now
The UK’s strong October didn’t brighten its dark outlook

$30 Billion Drug Deal

What’s Going On Here?

Biotech giant Amgen announced on Monday that it’s buying drugmaker Horizon Therapeutics in a deal worth almost $30 billion.

What Does This Mean?

Amgen just made a big move. The firm announced it’s buying Horizon for a staggering $26 billion, its biggest-ever deal, in a splurge that comes hot on the heels of the near $4 billion acquisition of ChemoCentryx earlier this year. No wonder it’s making moves: stiff competition and an upcoming patent expiry have hit Amgen’s top-selling arthritis drug for four straight quarters, and this acquisition will help the firm replenish its offerings with a crop of popular approved drugs. Case in point: the deal will see Amgen bulk up its portfolio with the eye disease treatment Tepezza, a drug that’s already a tidy money-maker.

Why Should I Care?

Zooming in: Pharma feeding time.
Horizon’s shares were down 27% earlier this year, which is probably a key reason that other pharma companies, including Sanofi and Johnson & Johnson, started sizing the firm up in the first place. No surprise: the biotech sector entered its biggest selloff since the early 2000s this year, and that led analysts to predict that drugmakers with deep pockets would snap up rivals and replenish their product pipelines. And they weren't far off: other standout deals include Johnson & Johnson's $17 billion acquisition of Abiomed last month and Pfizer's $12 billion purchase of Biohaven Pharmaceuticals in May.

The bigger picture: Festive shopping spree.
This week’s been a busy one for dealmakers, with firms rushing to get contracts signed and initialed before the holiday season kicks into gear. So far, Thoma Bravo’s announced an $8 billion takeover of spending-management platform Coupa, Novozymes has said it’s buying fellow enzyme-maker Chr. Hansen for around $12 billion, and Microsoft’s bitten off a $2 billion chunk of the London Stock Exchange. That’s a fat $70 billion in deals this week alone – not bad considering overall dealmaking’s down by a third this year (tweet this).

You might also like: The big opportunities behind big pharmaceutical companies.

Copy to share story: https://go.finimize.com/wp/news/30-billion-drug-deal/

🙋 Ask a question

Analyst Take

This Year Was A Scorcher, Inflation-Wise. What Will 2023 Be Like?

By Luke Suddards, Analyst

2022 has been the year of red-hot inflation.

In the US it hit a wallet-melting 9.1% in June, a level not seen in over 40 years. And ever since then, price pressures have been sliding lower.

Many (myself included) now believe we’ve seen peak inflation – and that 2023 will be the year of significant disinflation, with price pressures falling back down to between the 3 and 4% mark.

That’s today’s Insight: we’re looking at the four factors that’ll drive the cooldown in inflation.

Read or listen to the Insight here

Finimize x Revolut

Pretty good stuff, right? Our analysts write Insights like this every day, and you can read every single one of them with Finimize Premium.

There’s no better time to get started: our new partnership means you can get six free months of Finimize Premium and three free months of Revolut Premium if you sign up for Revolut today.

We’ll even send you £10 (or equivalent) to your Revolut account to get you started.

Unlock tomorrow’s biggest business opportunities

Good business ideas are a dime a dollar.

Good business models are harder to come by: after all, you’ll need a strong strategy and an even stronger balance sheet if you want to really establish your brand.

Enter Upexi (ticker: UPXI): the brand owner and aggregator buys profitable businesses and finds the right specialist to transform their operations, setting them up for higher revenue and profit.

So by investing in Upexi (one of the few public brand aggregators that you can invest in), you’d stake your claim in a diversified bunch of companies that are headed toward a pretty profit.

Get a piece of tomorrow’s biggest businesses with Upexi.

Check Out Upexi

Disclaimer

This content is for US investors only, if you are not a US investor please ignore this content. This content is a paid advertisement for Upexi (NASDAQ: UPXI) from Interactive Offers and Finimize. This is not Finimize editorial content. Finimize received a fixed fee for producing, hosting and promoting this content on behalf of Upexi, totalling $23,000. Other than the compensation received for this service, Finimize and its principals are not affiliated with either Interactive Offers or Upexi. Finimize and its principals have no ownership in Upexi. The content on this page should not be taken as advice, an endorsement, or a recommendation from Finimize and its principals to buy or sell any security. Finimize and its principals have not evaluated the accuracy of any claims made on this page. Finimize and its principals recommend that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky and capital is at risk. Past performance is not indicative of future results.

No Fall In Fall After All

What’s Going On Here?

Data out on Monday showed the British economy bounced back in October.

What Does This Mean?

Britain’s economy was unsteady on its feet when September began, and the double-blow of the late Queen’s funeral and a period of national mourning left the country totally out for the count. But the economy returned to growth in October, with consumer-facing services like hospitality springing back after two months on the slide. And as the weather cooled, some Brits helped the health sector by lapping up more vaccinations and Covid tests, while others buoyed up travel and headed for faraway hills. In fact, there was good news across the board, with output across services, manufacturing, and construction all improving. That meant the economy grew 0.5% from September to October, faster than the 0.4% economists were expecting.

Why Should I Care?

Zooming in: Three strikes, you’re out.
Still, compare the three months through October to the previous three-month period, and you’ll find that the economy actually shrank 0.3%. And the situation might be about to get even worse: after all, inflation’s still emptying households’ coffers, and healthcare, rail, and postal workers are all set to strike this month – meaning Britain’s poised for industrial disruption on a scale it hasn’t seen since the '80s. No wonder some experts think the economy’s destined to shrink this quarter.

The bigger picture: Hikes will hurt.
That dire outlook could make things even harder for the Bank of England, which'll be adding another rate hike to its ongoing anti-inflation crusade later this week. After all, it predicted last month that even without hikes, the economy will shrink in five of the next six quarters, until the end of 2023. So while investors generally think the central bank will steer a milder course and announce a hike of 0.5 percentage points this time around, the country’s probably in for a bruising whatever happens.

You might also like: It’s not just the UK – abrdn sees the whole world on the brink of recession.

Copy to share story: https://go.finimize.com/wp/news/no-fall-in-fall-after-all/

🙋 Ask a question

💬 Quote of the day

“The brain is a wonderful organ. It starts working the moment you get up in the morning and does not stop until you get into the office.”

– Robert Frost (an American poet)

Tweet this

You really made the last week special

It’s been an incredible week for Finimize, and we have you to thank for it.

You made our Modern Investor Summit a huge success, with around 15,000 amazing members of our community showing up to hear from speakers such as Cathie Wood, Wei Li, and Anthony “Pomp” Pompliano, not to mention firms like BlackRock, eToro, and Allianz Global Investors too.

Then we were featured in CNBC, Forbes, Business Insider, The Telegraph, and Sky News – yup, that’s all in the one week.

And to top it all off, our founder Maximilian Rofagha just made a live appearance on Yahoo Finance to discuss the results from our brand new “Modern Investor Survey”.

Check it out today, and find out what retail investors like you are really thinking.

View Our Post

🌍 Finimize Live

🥳 Coming Up This Week…

All events in UK time.

✍️ How To Protect Your Crypto In 2023: 11am, December 14th
🧠 Three Behavioral Biases To Avoid When Investing: 5pm, December 14th
🇺🇸 How To Prepare For What’s Next For The US Economy: 1pm, December 15th
🥂 The Best Luxury Stocks To Buy In 2023: 5pm, December 15th
🎙 Live Q&A With Finimize CEO Max Rofagha: 12pm, December 16th

👀 And After That…

🌪 Preparing Your Strategy for A Volatile 2023 and Beyond: 12pm, January 11th
📑 The Risks And Regulations When Investing In Crypto: 10am, January 27th

🎯 On Our Radar

Monkey business. IKEA’s famous simian is still thriving ten years later.
Now that’s a long-term forecast. Here’s how the world might look if humans are around in a million years.
Goodbye, stomach rumblings. Simple, quick work-from-home meals to stop you skipping lunch.
Ugly mugs. This is why we make snap judgments about folk based on their faces.
Chronically online. The internet’s full of uniquely, hilariously silly opinions.

❤️ Share with a friend

Your Referrals: 0

Thanks for reading Reader. If you liked today's brief, we'd love for you to share it with a friend.

Share your unique link:

https://finimize.com/invite/?kid=177ZWC

You stay classy, Reader 😉

We’d love to hear your thoughts. Give feedback

Want to advertise with us too? Get in touch

Image Credits:

Image credits: Vecster - Shutterstock | Virtis - Shutterstock

Preferences:

Update your email or change preferences

View in browser

Unsubscribe from all Finimize Emails

😴

Crafted by Finimize Ltd. | Bow Bells House, Bread Street, London, EC4M 9HH

All content provided by Finimize Ltd. is for informational and educational purposes only and is not meant to represent trade or investment recommendations. You signed up to this mailing list at finimize.com or through one of our partners. © Finimize 2021

Finimize - 📉 2023 has price-drop potential

Today's big stories

$30 Billion Drug Deal

What’s Going On Here?

What Does This Mean?

Why Should I Care?

This Year Was A Scorcher, Inflation-Wise. What Will 2023 Be Like?

Unlock tomorrow’s biggest business opportunities

No Fall In Fall After All

What’s Going On Here?

What Does This Mean?

Why Should I Care?

You really made the last week special

🥳 Coming Up This Week…

👀 And After That…

Older messages

💵 Here’s how TSMC raked it in

📊 This is how Howard Marks is investing

🇨🇳 Here’s why China pivoted

🌞 Solar’s looking sunny

🛢 Oil is touch and go

You Might Also Like

The Price America Paid For Its First Big Immigration Crackdown

Climate and monetary policy series

Some implications of climate policy for monetary policy

🤖 Amazon's buddy

After Return on Equity

This pattern has averaged an 85% return per year since 2020

Longreads + Open Thread

Call me Neo, cause I just plugged into the Matrix

🪙 Big on bitcoin

In times of transition, investors search for reliable investments, like this…